With streamlined processes tailored to accommodate a diverse range of project requirements from research through commercial manufacturing, the EffiX™ platform accelerates the advancement of innovative ...

WuXi Biologics differentiates itself from other global well-established contract development and manufacturing organizations, with its “follow-and-win the molecule” and the “global dual ...

January 6, 2025 China's WuXi Biologics to sell Irish vaccine facility to Merck as US curbs loom China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker ...

WuXi Biologics has launched the E coli expression system, EffiX, designed to enhance the production of recombinant proteins ...

WUXI, China, Feb. 26, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it ...

Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, March 10, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development ...

EffiXTM is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a ...

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been included in the S&P Global Sustainability ...

To address the challenges in producing these biomolecules, WuXi Biologics has introduced the EffiX™ platform, which enables the development and manufacturing of microbial-derived biologics with high ...